What Supplements to Take on Ozempic, Wegovy, and Mounjaro

Why Supplements Matter More on GLP-1 Medications

GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Saxenda) — suppress appetite so effectively that most users cut their caloric intake by 30–50% within the first weeks of treatment. That is precisely the point. But dramatically reduced food volume means dramatically reduced micronutrient intake, and most people starting these medications aren't eating particularly nutrient-dense diets to begin with.

A 2023 analysis published in Obesity Reviews noted that caloric restriction of this magnitude — even short-term — consistently produces measurable declines in zinc, magnesium, B-vitamins, vitamin D, and essential fatty acids unless those nutrients are deliberately supplemented (Churuangsuk et al., Obesity Reviews 2022; PMID: 35181980). On GLP-1 therapy, the problem compounds: nausea and food aversions make it harder to eat the high-quality protein and vegetables that would otherwise offset some of those losses.

The result is a supplement landscape that matters far more on GLP-1 medications than during routine dieting. This guide covers what the evidence actually says about the supplements to take with Ozempic and other GLP-1 drugs — organized by mechanism and priority.

---

Semaglutide Nutrient Deficiency: The Gaps Most People Miss

Before getting to what to take, it helps to understand what goes missing — and why.

Protein and Amino Acids

This is the most critical gap, and it's not technically a micronutrient deficiency, but it drives everything downstream. When you eat 800–1,200 calories per day on GLP-1 therapy, hitting 1.2–1.6 g of protein per kilogram of body weight — the range broadly supported for muscle preservation during weight loss — becomes extremely difficult from food alone.

A landmark 2022 NEJM trial of semaglutide 2.4mg (Wegovy dose) found that participants lost an average of 15.3% of body weight over 68 weeks, but body composition data showed that roughly 25–39% of the weight lost was lean mass (Wilding et al., NEJM 2021; PMID: 33567185). That is a significant fraction of muscle walking out the door with the fat.

When protein intake is insufficient during caloric restriction, the body accelerates muscle catabolism to meet gluconeogenic demand. This is why leucine-rich protein supplementation — from whey, casein, or a high-quality plant blend — is the single highest-leverage intervention for GLP-1 users.

Evidence-based target: Aim for 1.2–1.6 g protein/kg body weight per day. For most GLP-1 users eating reduced volumes, that means 25–40g of supplemental protein daily from a shake or powder.

Vitamin B12

GLP-1 drugs slow gastric emptying, which reduces the efficiency of intrinsic factor-mediated B12 absorption from food. There is also a simple volume effect: if you're eating half as much meat, eggs, and dairy, you're consuming half as much dietary B12.

Subclinical B12 insufficiency (serum B12 < 300 pg/mL) is already common in the general population — estimates suggest 6% of adults under 60 are deficient, rising to 20% over 60 (NIH Office of Dietary Supplements, 2023). GLP-1-induced gastroparesis compounds this risk meaningfully. Symptoms of B12 insufficiency — fatigue, tingling extremities, brain fog, mood instability — are often misattributed to GLP-1 side effects.

Methylcobalamin (the active, methylated form) at 1,000–2,000 mcg daily is the preferred supplemental form, bypassing the intrinsic factor pathway via passive absorption at higher doses.

Vitamin D3 and K2

Vitamin D is a fat-soluble vitamin. During aggressive caloric restriction and fat malabsorption, circulating 25(OH)D levels tend to fall. A 2021 systematic review in Nutrients confirmed that bariatric surgery patients — who experience the most extreme dietary restriction — show vitamin D deficiency rates exceeding 50% post-operatively without supplementation (Pellegrini et al., Nutrients 2021; PMID: 33669073). GLP-1-driven caloric restriction isn't as extreme as surgery, but the directional risk is real.

Vitamin D3 (cholecalciferol) paired with K2 as MK-7 (menaquinone-7) is the preferred combination: D3 raises serum 25(OH)D efficiently, while K2-MK-7 activates matrix Gla protein and osteocalcin, directing calcium into bone rather than soft tissue. The clinical dose used in most outcome trials ranges from 1,000–5,000 IU D3 with 100–200 mcg K2-MK-7.

Magnesium

Magnesium is involved in over 300 enzymatic reactions, including insulin signaling, muscle contraction, sleep regulation, and HPA axis function. It is also one of the first minerals depleted during caloric restriction, particularly when whole grain and legume consumption drops.

Low magnesium status is independently associated with insulin resistance (Guerrero-Romero & Rodríguez-Morán, Diabetes & Metabolism 2011; PMID: 21703900), which means GLP-1 users — most of whom carry some degree of metabolic dysfunction — have elevated baseline risk. Magnesium glycinate (the amino acid chelate form) is the best-tolerated high-bioavailability option because it avoids the laxative effect of magnesium oxide or sulfate at therapeutic doses.

Zinc

Zinc is critical for immune function, taste and smell perception, wound healing, and — critically for GLP-1 users — insulin synthesis and secretion. The pancreatic beta cell uses zinc in the crystallization of insulin, and zinc deficiency measurably impairs glucose regulation (Jayawardena et al., Diabetology & Metabolic Syndrome 2012; PMID: 22748092). Because GLP-1 drugs work partly through improved insulin dynamics, maintaining adequate zinc status may amplify the metabolic benefit.

Zinc also plays a role in appetite regulation: zinc deficiency is a recognized cause of taste dysgeusia, which can make GLP-1-induced food aversions worse. Zinc picolinate or zinc bisglycinate at 15–25 mg/day is appropriate for most adults during GLP-1 treatment.

Omega-3 Fatty Acids (EPA/DHA)

Omega-3s have well-documented anti-inflammatory and cardiometabolic effects, but their relevance for GLP-1 users goes further. EPA and DHA support muscle protein synthesis signaling through mTOR pathways, independently of protein intake (Smith et al., American Journal of Clinical Nutrition 2011; PMID: 21159787). They also reduce triglycerides — which are frequently elevated in the metabolic syndrome populations most likely to use GLP-1 drugs.

Furthermore, omega-3 supplementation has been shown to modestly reduce visceral adiposity and improve insulin sensitivity, effects that are complementary to semaglutide's mechanism. The clinical effective range is 1.8–3.6g combined EPA+DHA daily — most fish oil capsules contain only 0.3g per capsule, meaning you need 6–12 standard capsules to reach this dose. Higher-concentration options (e.g., 1g EPA+DHA per capsule) are preferable.

---

GLP-1 Supplement Protocol: How to Structure Your Regimen

Knowing which supplements to take is one thing. Knowing when and in what combination they work together is another. Here is a structured, evidence-based GLP-1 supplement protocol.

Morning (with or before your first meal)

1. Vitamin D3 + K2 (MK-7) — fat-soluble; take with whatever fat you're eating, even a small amount. Dose: 2,000–5,000 IU D3 + 100–200 mcg K2-MK-7.
2. Omega-3 (EPA/DHA) — take with a meal to maximize absorption and minimize fishy reflux. Dose: target 1.8–3g combined EPA+DHA.
3. Zinc — best absorbed in the morning, separate from calcium-rich foods. Dose: 15–25 mg zinc picolinate or bisglycinate.

With a Protein-Rich Meal or Post-Workout

1. Protein supplement — 25–40g leucine-rich protein (whey isolate, casein, or high-quality plant blend). If GLP-1 nausea limits solid food, a protein shake is often better tolerated than a chicken breast.
2. CoQ10 / Ubiquinol — fat-soluble; take with a meal. Supports mitochondrial energy production and is particularly relevant if you are also on a statin (which depletes CoQ10). Dose: 100–200 mg ubiquinol.

Evening

1. Magnesium Glycinate — evening dosing supports sleep quality and overnight muscle recovery. Dose: 300–400 mg elemental magnesium as glycinate.
2. Methylcobalamin (B12) — 1,000–2,000 mcg sublingual or oral. Can be taken any time but pairs well with the evening routine.

Notes on Interaction Safety

None of the supplements above are contraindicated with GLP-1 medications themselves. The primary interaction risks are with other medications GLP-1 users commonly take: metformin (which depletes B12, making supplementation even more critical), statins (which deplete CoQ10), and PPIs (which reduce magnesium absorption). Always review your full supplement and medication stack with your prescriber.

For a broader look at safely combining multiple supplements, see our supplement stacking guide on how to combine supplements safely.

---

Ozempic Muscle Loss Supplements: Protecting Your Lean Mass

Of all the concerns GLP-1 users raise in clinical practice and online communities, muscle loss is the most consistent — and the most underaddressed by prescribers. Let's look at what the evidence actually supports for mitigating muscle loss on GLP-1 therapy.

Why GLP-1 Drugs Cause Muscle Loss

GLP-1 receptor agonists suppress appetite without discrimination — they reduce overall caloric intake, not just fat-targeted caloric intake. In the absence of sufficient protein and resistance exercise, the body in a large caloric deficit will catabolize lean tissue. The STEP 1 trial (Wilding et al., PMID: 33567185) showed 15.3% total weight loss with approximately 1–2 kg of lean mass lost even in that highly controlled research setting.

Real-world GLP-1 users, who may not be following supervised protein protocols or structured resistance training, may experience even greater proportional lean mass loss. Some clinicians informally report that lean mass loss in unsupported GLP-1 users can constitute 35–40% of total weight lost.

Leucine and Branch-Chain Amino Acids (BCAAs)

Leucine is the rate-limiting amino acid for muscle protein synthesis. It directly activates mTORC1, the cellular signal that triggers the anabolic machinery in skeletal muscle. A meta-analysis in Clinical Nutrition found that leucine supplementation significantly attenuated muscle loss during caloric restriction compared to control (Ispoglou et al., Clinical Nutrition 2021).

For GLP-1 users who struggle to eat enough total protein, leucine-enriched protein powders (whey is naturally high in leucine at ~10% by weight) or standalone BCAA supplements (2:1:1 leucine:isoleucine:valine ratio, 5–10g doses) can bridge the anabolic gap.

Creatine Monohydrate

Creatine is one of the most studied ergogenic supplements with one of the strongest safety profiles in sports nutrition. More relevant for GLP-1 users: creatine has been shown to preserve lean mass during caloric restriction and attenuate the decline in physical performance that accompanies significant weight loss.

A 2021 systematic review in Journal of Strength and Conditioning Research found that creatine supplementation (3–5 g/day) combined with resistance training produced significantly greater lean mass retention versus resistance training alone during energy-restricted periods. Creatine works by replenishing phosphocreatine in muscle cells, allowing higher training volume — which itself is the strongest stimulus for muscle retention.

Dose: 3–5 g creatine monohydrate daily (no loading phase required for most users; loading phases may worsen GLP-1-related GI symptoms).

HMB (Beta-Hydroxy Beta-Methylbutyrate)

HMB is a metabolite of leucine that has anti-catabolic properties independent of mTORC1 stimulation. It works primarily by inhibiting the ubiquitin-proteasome pathway — one of the mechanisms responsible for muscle breakdown during caloric deficit. A review in Nutrition & Metabolism found HMB supplementation (3 g/day) reduced markers of muscle breakdown and preserved lean mass during weight loss interventions.

While the evidence base for HMB is not as extensive as creatine or protein, it has particular appeal for older GLP-1 users (over 50) where baseline rates of sarcopenia make muscle preservation more urgent.

Resistance Training Remains Non-Negotiable

No supplement replaces the anabolic signal of resistance exercise. The combination of adequate protein, leucine, and 2–4 sessions per week of resistance training is the evidence-based standard for muscle preservation during GLP-1 therapy. Supplements amplify the signal — they don't generate it.

See our related coverage on what causes muscle loss in menopause for a deeper look at how hormonal status and caloric restriction interact — much of which is directly applicable to GLP-1-induced muscle loss regardless of menopause status.

---

Mounjaro Supplement Stack: Tirzepatide-Specific Considerations

Mounjaro (tirzepatide) and its weight-loss-approved sibling Zepbound act on both GLP-1 and GIP receptors — a dual agonist mechanism that produces greater average weight loss than single-agonist semaglutide. In the SURMOUNT-1 trial, tirzepatide 15mg produced a mean weight loss of 20.9% over 72 weeks (Jastreboff et al., NEJM 2022; PMID: 35658024), compared to ~15% for Wegovy.

This greater weight loss magnitude has important implications for nutrient depletion and muscle loss risk:

• Greater total caloric restriction means greater cumulative micronutrient deficit
• Greater lean mass loss in absolute terms — even if the percentage of weight lost as lean mass is similar, the absolute kg lost is higher
• Faster weight loss trajectory in many users, leaving less time for the body to adapt

Does the Supplement Protocol Differ from Semaglutide?

The core supplement needs are the same, but tirzepatide users should be especially diligent about:

If you are using tirzepatide and also managing cholesterol — which is common in this population — reviewing what supplements affect cholesterol ratio can help you prioritize additional lipid-supportive ingredients alongside your core GLP-1 stack.

---

GLP-1 and Blood Sugar: Supplement Support for Glucose Regulation

GLP-1 drugs work primarily by improving insulin secretion, slowing gastric emptying, and reducing glucagon release. But several supplements have complementary mechanisms that may enhance glycemic outcomes — and are worth including for users with prediabetes, type 2 diabetes, or elevated fasting glucose.

Berberine

Berberine activates AMP-activated protein kinase (AMPK), an energy-sensing enzyme that improves insulin sensitivity and reduces hepatic glucose output — a mechanism broadly similar to metformin. Multiple meta-analyses have confirmed berberine's blood glucose-lowering effect, with one 2019 systematic review finding HbA1c reductions of 0.5–1.5% in T2D populations (Liang et al., Medicine 2019; PMID: 30593163).

Importantly, if you are on metformin alongside your GLP-1 drug, adding berberine may have additive glucose-lowering effects. Monitor blood glucose accordingly and discuss with your provider.

Dose: 500 mg berberine three times daily with meals.

Alpha-Lipoic Acid (ALA)

ALA is a mitochondrial antioxidant that also improves insulin-stimulated glucose uptake in skeletal muscle. It has been used in Europe for decades as a pharmaceutical treatment for diabetic neuropathy. A meta-analysis in Diabetic Medicine found 600–1,800 mg/day ALA meaningfully reduced fasting glucose and HOMA-IR in T2D patients.

For GLP-1 users experiencing peripheral neuropathy symptoms or who want to support insulin sensitivity beyond what the drug provides, ALA is one of the more evidence-backed additions.

Chromium Picolinate

Chromium potentiates insulin action by improving insulin receptor signaling. The evidence is modest but consistent: 200–1,000 mcg chromium picolinate daily has been shown to reduce fasting glucose and HbA1c in populations with insulin resistance. It is inexpensive, well-tolerated, and a reasonable complement to GLP-1 therapy for users with glucose dysregulation.

For users with elevated fasting glucose looking for a structured approach, see how long it takes to lower fasting glucose for a deeper evidence-based protocol.

---

Gut Health and GLP-1 Tolerance: Supporting Digestion During Treatment

Nausea, constipation, and bloating are the most commonly reported side effects of GLP-1 therapy — and they're not just uncomfortable, they can make it harder to eat enough protein and absorb the micronutrients you're supplementing. Supporting GI function is therefore a critical pillar of any GLP-1 supplement protocol.

Digestive Enzymes

Reduced gastric motility from GLP-1 therapy means food sits in the stomach longer and may be incompletely broken down before reaching the small intestine. Broad-spectrum digestive enzymes (including protease, lipase, and amylase) taken with meals can reduce bloating and improve nutrient extraction from the smaller quantities of food you're eating.

Probiotics and Prebiotics

Gut microbiome composition influences GLP-1 secretion endogenously — certain Lactobacillus and Bifidobacterium strains have been shown to upregulate intestinal L-cell GLP-1 production (Deleu et al., Gut 2021). There is a plausible case for multi-strain probiotic supplementation both enhancing the drug's mechanism and reducing GI side effects through microbiome stabilization.

Look for products containing documented strains (Lactobacillus acidophilus NCFM, Bifidobacterium lactis Bi-07) with colony counts ≥ 10 billion CFU and storage stability data.

Ginger Extract

Ginger (as standardized Zingiber officinale extract, 1–2g daily) has a well-established evidence base for reducing nausea, including chemotherapy-induced nausea, which shares mechanistic overlap with GLP-1-induced nausea via the 5-HT3 pathway. It is safe, well-tolerated, and can meaningfully reduce the GI side effect burden that causes many patients to reduce their GLP-1 dose prematurely.

---

What This Means for Your Formula

For users on GLP-1 medications, Ones builds custom formulas based on lab results, wearable data, and health history — which means the AI can identify exactly which gaps your blood work reveals and calibrate doses accordingly, rather than applying a generic GLP-1 template.

Several Ones ingredients are particularly relevant to the GLP-1 user population:

Vitamin D3 + K2 (MK-7): Ones sources cholecalciferol paired with menaquinone-7, the bioactive K2 form used in the Rotterdam Study on cardiovascular outcomes. Dosing is calibrated to your baseline 25(OH)D from your blood panel — not a flat dose. For GLP-1 users with documented vitamin D insufficiency (25(OH)D < 30 ng/mL), the formula will support repletion before shifting to maintenance.

Magnesium Complex: Ones includes a magnesium glycinate-dominant blend formulated for bioavailability without GI disturbance — critical for GLP-1 users already managing nausea and loose stools. Elemental magnesium in the glycinate form is better absorbed and retained than oxide forms, which matters when your dietary magnesium is suppressed by caloric restriction.

Omega-3 (EPA/DHA): Ones includes concentrated EPA and DHA calibrated to cardiovascular and inflammatory need — particularly relevant for GLP-1 users who frequently present with elevated triglycerides and systemic inflammation alongside metabolic syndrome. The anti-inflammatory effect of omega-3s also complements the muscle protein synthesis signaling support that GLP-1 users need to protect lean mass.

For GLP-1 users who are also navigating significant muscle loss concerns or managing their cholesterol alongside weight loss, Ones' AI practitioner can map the full picture — identifying where your labs and biomarkers diverge from the supplement assumptions most protocols make.

---

Supplements to Avoid or Use Cautiously on GLP-1 Medications

Not every supplement marketed for weight loss or metabolic health is appropriate for GLP-1 users. A few to approach with caution:

High-Dose Iron (Without Testing)

GLP-1-induced reduced food intake can theoretically reduce dietary iron, but iron supplementation without confirmed deficiency via serum ferritin and iron panel causes oxidative stress and GI irritation — particularly problematic when the gut is already sensitized by GLP-1 side effects. Test before supplementing iron.

Fat-Soluble Vitamin Megadosing

Vitamin A and vitamin E in high doses are hepatotoxic and may be disproportionately accumulated during rapid fat loss as adipose tissue releases stored fat-soluble compounds. Stick to RDA-level vitamin A and avoid high-dose vitamin E (> 400 IU/day) during active GLP-1-induced weight loss.

Stimulant-Based Fat Burners

Caffeine-heavy thermogenic stacks (common in weight loss supplement marketing) can worsen GLP-1-associated nausea, raise heart rate, and interact with blood pressure — a concern for the significant proportion of GLP-1 users who carry hypertension alongside metabolic syndrome.

For a broader look at whether weight loss supplement stacks actually add value alongside pharmaceutical intervention, our weight loss supplement stack clinical trial review offers a balanced evidence-based perspective.

---

Tracking Your Progress: When to Reassess Your GLP-1 Supplement Stack

Supplementing on GLP-1 therapy is not a set-and-forget exercise. Your needs change as you lose weight, as your dietary patterns evolve, and as your labs shift in response to treatment. A practical schedule:

• At 3 months: Retest 25(OH)D, serum B12, magnesium RBC (red blood cell magnesium is a more sensitive marker than serum), fasting glucose, lipid panel, and CBC. Adjust doses based on results.
• At 6 months: Full metabolic panel including zinc, ferritin, and CRP. Body composition (DEXA if available) to quantify lean vs fat mass loss and calibrate protein strategy.
• Annually: Comprehensive review integrating wearable data, lab trends, and updated health goals.

This is precisely the kind of longitudinal data integration where AI-driven platforms like Ones add their greatest value — comparing your current labs against your baseline trajectory, identifying emerging deficiencies before they become symptomatic, and updating your formula accordingly.

---

Key Takeaways

• Nutrient gaps are real on GLP-1 therapy. Caloric restriction of 30–50% consistently depletes B12, vitamin D, magnesium, zinc, and essential fatty acids — most of which require active supplementation to replace.
• Muscle loss is the highest-stakes risk. Up to 25–40% of weight lost on GLP-1 medications can be lean mass without adequate protein (1.2–1.6 g/kg/day), leucine, creatine, and resistance training.
• Tirzepatide (Mounjaro) users have elevated nutritional risk due to greater total weight loss, requiring especially diligent attention to protein, creatine, and micronutrient support.
• Complementary glucose support from berberine, alpha-lipoic acid, and chromium picolinate may enhance GLP-1 drug outcomes — but requires monitoring, particularly if metformin is co-prescribed.
• GI support matters. Digestive enzymes, ginger extract, and probiotics can reduce the side effect burden that causes premature dose reduction or discontinuation.
• Reassess every 3–6 months. Your supplement needs on GLP-1 therapy evolve with your labs, your weight, and your diet. A personalized, lab-calibrated approach consistently outperforms generic stacks.

---

This article is for informational purposes only and does not constitute medical advice. Consult your prescribing physician or a registered dietitian before making changes to your supplement regimen, particularly if you are managing diabetes, cardiovascular disease, or taking prescription medications alongside GLP-1 therapy.